$TVTX
Travere Therapeutics Inc Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000143853317000034 Filed on November 07, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q4
Revenue	$42.00K	$40.00K	$37.33M
YoY Change	-99.89%	-99.88%	22.6%
Cost Of Revenue	$1.170M	$925.0K	$1.200M
YoY Change	-2.5%	-41.2%	57.89%
Gross Profit	$41.00M	-$885.0K	$36.12M
YoY Change	13.51%	-102.73%	21.66%
Gross Profit Margin	97619.05%	-2212.5%	96.77%
Selling, General & Admin	$22.40M	$24.85M	$22.58M
YoY Change	-0.8%	5.91%	19.16%
% of Gross Profit	54.63%		62.51%
Research & Development	$19.49M	$19.61M	$20.00M
YoY Change	-2.55%	6.5%	30.12%
% of Gross Profit	47.54%		55.37%
Depreciation & Amortization	$4.460M	$4.620M	$4.190M
YoY Change	6.44%	12.96%	5.54%
% of Gross Profit	10.88%		11.6%
Operating Expenses	$57.35M	$50.95M	$55.55M
YoY Change	3.25%	-6.2%	21.68%
Operating Profit	-$15.18M	-$10.61M	-$18.22M
YoY Change	-16.71%	-47.93%	19.85%
Interest Expense	-$4.230M	-$660.0K	-$1.290M
YoY Change	227.91%	120.74%	-69.36%
% of Operating Profit
Other Income/Expense, Net	$4.139M	-$8.409M	-$5.935M
YoY Change	-169.74%	-181.85%	-368.55%
Pretax Income	-$11.04M	-$19.02M	-$12.29M
YoY Change	-10.17%	-37.95%	-5.44%
Income Tax	$6.580M	-$1.223M	-$3.684M
% Of Pretax Income
Net Earnings	-$17.62M	-$17.79M	-$8.603M
YoY Change	104.79%	-52.05%	248.44%
Net Earnings / Revenue	-41947.62%	-44485.0%	-23.05%
Basic Earnings Per Share	-$0.45	-$0.46	-$0.23
Diluted Earnings Per Share	-$0.55	-$0.46	-$0.39
COMMON SHARES
Basic Shares Outstanding	39.31M shares	38.65M shares	37.73M shares
Diluted Shares Outstanding		38.65M shares

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$222.7M	$303.9M	$255.9M
YoY Change	-12.98%	10.78%	11.44%
Cash & Equivalents	$99.39M	$98.99M	$41.00M
Short-Term Investments	$123.3M	$204.9M	$214.9M
Other Short-Term Assets	$6.000M	$2.600M	$8.300M
YoY Change	-27.71%	-27.78%	-20.95%
Inventory	$5.351M	$4.318M	$2.826M
Prepaid Expenses
Receivables	$13.87M	$14.54M	$18.51M
Other Receivables	$0.00	$0.00	$46.90M
Total Short-Term Assets	$325.8M	$325.3M	$332.4M
YoY Change	-1.97%	-5.04%	10.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.230M	$2.717M	$2.587M
YoY Change	24.86%	611.26%	504.44%
Goodwill	$936.0K	$936.0K	$936.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles	$184.8M		$182.0M
YoY Change	1.52%		12.7%
Long-Term Investments	$0.00
YoY Change
Other Assets	$5.556M	$7.101M	$7.364M
YoY Change	-24.55%	259.73%	296.13%
Total Long-Term Assets	$194.5M	$195.2M	$192.9M
YoY Change	0.83%	2.81%	-8.27%
TOTAL ASSETS
Total Short-Term Assets	$325.8M	$325.3M	$332.4M
Total Long-Term Assets	$194.5M	$195.2M	$192.9M
Total Assets	$520.3M	$520.5M	$525.3M
YoY Change	-0.94%	-2.24%	2.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.94M	$7.370M	$7.522M
YoY Change	151.77%	140.38%	-1.53%
Accrued Expenses	$36.02M	$32.25M	$33.31M
YoY Change	8.14%	-20.12%	39.83%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$85.67M	$83.90M	$83.26M
YoY Change	2.89%	-2.43%	-4.28%
LONG-TERM LIABILITIES
Long-Term Debt	$45.10M	$44.90M	$44.40M
YoY Change	1.58%	1.35%	1.37%
Other Long-Term Liabilities	$2.472M	$3.808M	$4.010M
YoY Change	-38.35%	54.73%	30.79%
Total Long-Term Liabilities	$2.472M	$3.808M	$4.010M
YoY Change	-38.35%	54.73%	30.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$85.67M	$83.90M	$83.26M
Total Long-Term Liabilities	$2.472M	$3.808M	$4.010M
Total Liabilities	$227.2M	$216.0M	$217.5M
YoY Change	4.46%	-3.93%	2.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$177.7M	-$160.0M	-$113.1M
YoY Change	57.14%	53.21%	73.52%
Common Stock	$471.8M	$465.2M	$421.3M
YoY Change	11.98%	12.8%	15.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$293.1M	$304.5M	$307.8M
YoY Change
Total Liabilities & Shareholders Equity	$520.3M	$520.5M	$525.3M
YoY Change	-0.94%	-2.24%	2.54%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q4
OPERATING ACTIVITIES
Net Income	-$17.62M	-$17.79M	-$8.603M
YoY Change	104.79%	-52.05%	248.44%
Depreciation, Depletion And Amortization	$4.460M	$4.620M	$4.190M
YoY Change	6.44%	12.96%	5.54%
Cash From Operating Activities	-$860.0K	$6.200M	-$8.490M
YoY Change	-89.87%	33.91%	139.15%
INVESTING ACTIVITIES
Capital Expenditures	-$2.940M	-$3.740M	-$4.230M
YoY Change	-30.5%	34.53%	145.93%
Acquisitions
YoY Change
Other Investing Activities	$2.840M	$1.540M	$34.70M
YoY Change	-91.82%	-147.09%	-135.14%
Cash From Investing Activities	-$110.0K	-$2.180M	$30.47M
YoY Change	-100.36%	-63.97%	-130.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.370M	5.830M	-5.050M
YoY Change	-127.13%	44.31%	-510.57%
NET CHANGE
Cash From Operating Activities	-860.0K	6.200M	-8.490M
Cash From Investing Activities	-110.0K	-2.180M	30.47M
Cash From Financing Activities	1.370M	5.830M	-5.050M
Net Change In Cash	400.0K	9.850M	16.93M
YoY Change	-97.64%	275.95%	-116.47%
FREE CASH FLOW
Cash From Operating Activities	-$860.0K	$6.200M	-$8.490M
Capital Expenditures	-$2.940M	-$3.740M	-$4.230M
Free Cash Flow	$2.080M	$9.940M	-$4.260M
YoY Change	-148.83%	34.14%	132.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	rtrx	Legal Accrual Reversal LegalAccrualReversal	2967000	USD
	rtrx	Legal Accrual Reversal LegalAccrualReversal	0	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	1551000	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	1353000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39306699	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Retrophin, Inc.
	dei	Trading Symbol TradingSymbol	rtrx
CY2016Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	1597000	USD
CY2017Q3	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	1908000	USD
CY2016Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	7311000	USD
CY2017Q3	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	7218000	USD
CY2016Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3333000	USD
CY2017Q3	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	1933000	USD
CY2016Q4	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	8068000	USD
CY2017Q3	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	7393000	USD
CY2016Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	5766000	USD
CY2017Q3	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	6144000	USD
CY2017Q3	rtrx	Accrued Royaltyand Contingent Consideration Due AccruedRoyaltyandContingentConsiderationDue	13500000	USD
CY2017Q3	rtrx	Accrued Royaltyand Contingent Consideration Due Rolling After Year Five AccruedRoyaltyandContingentConsiderationDueRollingAfterYearFive	3500000	USD
CY2017Q3	rtrx	Accrued Royaltyand Contingent Consideration Due Rolling Year Twoand Three AccruedRoyaltyandContingentConsiderationDueRollingYearTwoandThree	4000000	USD
CY2017Q3	rtrx	Accrued Royaltyand Contingent Consideration Due Rolling Years Fourand Five AccruedRoyaltyandContingentConsiderationDueRollingYearsFourandFive	4000000	USD
CY2017Q3	rtrx	Accrued Royaltyand Contingent Consideration Next Rolling Twelve Months AccruedRoyaltyandContingentConsiderationNextRollingTwelveMonths	2000000	USD
CY2016Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	16150000	USD
CY2017Q3	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	16941000	USD
CY2016Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	71328000	USD
CY2017Q3	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	75974000	USD
CY2016Q3	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	5256000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	10741000	USD
CY2017Q3	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	4429000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	11057000	USD
CY2017Q3	rtrx	Contractual Obligation Due In Rolling After Year Five ContractualObligationDueInRollingAfterYearFive	9021000	USD
CY2017Q3	rtrx	Contractual Obligation Due In Rolling Year Four And Five ContractualObligationDueInRollingYearFourAndFive	9843000	USD
CY2017Q3	rtrx	Contractual Obligation Due In Rolling Year Two And Three ContractualObligationDueInRollingYearTwoAndThree	58002000	USD
CY2017Q3	rtrx	Contractual Obligation Next Rolling Twelve Months ContractualObligationNextRollingTwelveMonths	8591000	USD
CY2016Q4	rtrx	Government Rebates Payable GovernmentRebatesPayable	6967000	USD
CY2017Q3	rtrx	Government Rebates Payable GovernmentRebatesPayable	5614000	USD
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1500000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.07
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-57000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-57000	USD
	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	1605000	USD
	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	651000	USD
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1500000	USD
CY2017Q3	rtrx	Purchase Obligation Duein Rolling Year Fourand Five PurchaseObligationDueinRollingYearFourandFive	0	USD
CY2017Q3	rtrx	Purchase Obligation Duein Rolling Year Twoand Three PurchaseObligationDueinRollingYearTwoandThree	37000	USD
CY2017Q3	rtrx	Purchase Obligation Duein Rollingafter Year Five PurchaseObligationDueinRollingafterYearFive	0	USD
CY2017Q3	rtrx	Purchase Obligation Next Rolling Twelve Months PurchaseObligationNextRollingTwelveMonths	350000	USD
CY2017Q3	rtrx	Reclassification Of Derivative Liability To Equity ReclassificationOfDerivativeLiabilityToEquity	0	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7522000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	7370000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18510000	USD
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14543000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-853000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-972000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	33308000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32253000	USD
CY2016Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2000000	USD
CY2017Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2000000	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7441000	USD
CY2017Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6885000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-490000	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-595000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	421309000	USD
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	465148000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7748000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22034000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6960000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21292000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	491000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	460000	USD
CY2016Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4069000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11864000	USD
CY2017Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4506000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12996000	USD
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11411000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10869000	shares
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11461000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10936000	shares
CY2016Q4	us-gaap	Assets Assets	525282000	USD
CY2017Q3	us-gaap	Assets Assets	520510000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	332352000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	325339000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	214871000	USD
CY2017Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	204882000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	19000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	550000	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	305000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	215414000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	214871000	USD
CY2017Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	205168000	USD
CY2017Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	204882000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-772000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-885000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37805000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23895000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41002000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98991000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-13910000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	57989000	USD
CY2017Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	607481	shares
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1766905	shares
CY2017Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1159424	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37906669	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39280702	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37906669	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39280702	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36788000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39678000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17813000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42218000	USD
CY2017Q3	us-gaap	Contractual Obligation ContractualObligation	85457000	USD
CY2016Q4	us-gaap	Convertible Debt ConvertibleDebt	44422000	USD
CY2017Q3	us-gaap	Convertible Debt ConvertibleDebt	44911000	USD
CY2017Q3	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	71700000	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1573000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3351000	USD
CY2017Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	925000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2431000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-10999000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7811000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2017Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	4848000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	6425000	USD
CY2017Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11953000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13336000	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	22440000	USD
CY2017Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	20140000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.00
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.10
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.07
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.10
CY2016Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.211
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.132
CY2017Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.064
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.110
CY2017Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10126000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4849000	USD
CY2017Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8901000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8921000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	33497000	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	46680000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	215540000	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	226249000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	182043000	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	179569000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1074000	USD
CY2016Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	17000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	19000	USD
CY2017Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-102000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-361000	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-5212000	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2016Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2017Q3	us-gaap	Goodwill Goodwill	936000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30646000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45294000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19017000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-47325000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6467000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5994000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1200000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1223000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5212000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5200000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3278000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	425000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2544000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4064000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	712000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	319000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	937000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3747000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3879000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2561000	USD
CY2016Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-299000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-609000	USD
CY2017Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-65000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-855000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1490000	USD
CY2017Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1552000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	2826000	USD
CY2017Q3	us-gaap	Inventory Net InventoryNet	4318000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1336000	USD
CY2017Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2766000	USD
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	600000	USD
CY2017Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	500000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	217515000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	215990000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	525282000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	520510000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	83262000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	83904000	USD
CY2016Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	5212000	USD
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	5212000	USD
CY2017Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	2000000	USD
CY2016Q4	us-gaap	Marketable Securities MarketableSecurities	214871000	USD
CY2017Q3	us-gaap	Marketable Securities MarketableSecurities	204882000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1195000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4084000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-20100000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	45705000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	5052000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	8257000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-37113000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-39300000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-17794000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-42113000	USD
CY2016Q3	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-37113000	USD
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-39300000	USD
CY2017Q3	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-17794000	USD
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-42113000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10274000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1437000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5302000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8409000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8711000	USD
CY2016Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	46849000	USD
CY2017Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0	USD
CY2017Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	54317000	USD
	us-gaap	Operating Expenses OperatingExpenses	136257000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	50948000	USD
	us-gaap	Operating Expenses OperatingExpenses	151374000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-20372000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39992000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10608000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38614000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	17015000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Rolling After Year Five OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive	4862000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Four And Five OperatingLeasesFutureMinimumPaymentsDueInRollingYearFourAndFive	5010000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Two And Three OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwoAndThree	4817000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Next Rolling Twelve Months OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths	2326000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7364000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7101000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	308000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-397000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	83000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	256000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1842000	USD
CY2017Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4048000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4010000	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3808000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	11000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-95000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	151000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	156000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	557000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1065000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	4339000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	5006000	USD
CY2017Q3	us-gaap	Payments For Restructuring PaymentsForRestructuring	0	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	898000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	152016000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	67552000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	500000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7632000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	9632000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	61000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4831000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2605000	USD
CY2016Q4	us-gaap	Prepaid Taxes PrepaidTaxes	3463000	USD
CY2017Q3	us-gaap	Prepaid Taxes PrepaidTaxes	0	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	5998000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3645000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-439000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	92609000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	76826000	USD
	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	47500000	USD
	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	47500000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2225000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7695000	USD
CY2017Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3600000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3600000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2587000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2717000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	58000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	321000	USD
CY2017Q3	us-gaap	Purchase Obligation PurchaseObligation	387000	USD
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	750000	USD
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	750000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18414000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50758000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19610000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58592000	USD
CY2017Q3	us-gaap	Restructuring And Related Cost Expected Cost Remaining1 RestructuringAndRelatedCostExpectedCostRemaining1	1400000	USD
CY2016Q3	us-gaap	Restructuring Charges RestructuringCharges	396000	USD
	us-gaap	Restructuring Charges RestructuringCharges	481000	USD
CY2017Q1	us-gaap	Restructuring Charges RestructuringCharges	498000	USD
CY2017Q2	us-gaap	Restructuring Charges RestructuringCharges	981000	USD
CY2017Q3	us-gaap	Restructuring Charges RestructuringCharges	1132000	USD
	us-gaap	Restructuring Charges RestructuringCharges	2611000	USD
CY2017Q3	us-gaap	Restructuring Costs RestructuringCosts	1131000	USD
	us-gaap	Restructuring Costs RestructuringCosts	2611000	USD
CY2016Q4	us-gaap	Restructuring Reserve RestructuringReserve	893000	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	33945000	USD
CY2017Q2	us-gaap	Restructuring Reserve RestructuringReserve	1420000	USD
CY2017Q3	us-gaap	Restructuring Reserve RestructuringReserve	2551000	USD
CY2017Q3	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	0	USD
	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	-55000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113056000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-160037000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	96265000	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36728911	shares
CY2017Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	40340000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	112760000	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23466000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	65714000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24852000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	74683000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	22034000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	21292000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4300000	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	15.64
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	307767000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	304520000	USD
CY2016Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	USD
CY2017Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	1152000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1500000	USD
CY2017Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1500000	USD
CY2017Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36980356	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38654086	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38301893	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36980356	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36728911	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38654086	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38301893	shares
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">BASIS OF PRESENTATION</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the 2016 10-K filed with the SEC on March 1, 2017. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information, the instructions for Form 10-Q and the rules and regulations of the SEC. Accordingly, since they are interim statements, the accompanying condensed consolidated financial statements do not include all of the information and notes required by GAAP for annual financial statements, but reflect all adjustments consisting of normal, recurring adjustments, that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of the results that may be expected for any future periods. The </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December 31, 2016</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> balance sheet information was derived from the audited financial statements as of that date.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"> </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation.</font></div></div>
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#006ebf;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In this Quarterly Report on Form 10-Q, unless the context requires otherwise, the terms “we”, “our”, “us”, “Retrophin” and the “Company” refer to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on the development, acquisition and commercialization of therapies for the treatment of serious or rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious or rare diseases and that we believe offer attractive growth characteristics. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">Research and Development Programs:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Fosmetpantotenate, also known as RE-024, a novel small molecule, is being developed as a potential treatment for pantothenate kinase-associated neurodegeneration (“PKAN”). PKAN is a genetic neurodegenerative disorder that is typically diagnosed in the first decade of life. Consequences of PKAN include parkinsonism, dystonia, and other severe systemic manifestations. Fosmetpantotenate (RE-024) is a phosphopantothenate replacement therapy that aims to restore levels of this key substrate in PKAN patients. Certain international health regulators have approved the initiation of dosing fosmetpantotenate (RE-024) in PKAN patients under physician-initiated studies in accordance with local regulations in their respective countries. The Company filed a U.S. Investigational New Drug ("IND") for fosmetpantotenate (RE-024) with the FDA in the first quarter of 2015 to support the commencement of a Company-sponsored Phase 1 study, which was successfully completed during 2015. The FDA granted fosmetpantotenate (RE-024) orphan drug designation in May 2015 and fast track designation in June 2015. In February 2016, the Company announced fosmetpantotenate (RE-024) was granted orphan drug designation by the European Commission. In November 2016, the Company announced that it had reached an agreement with the FDA under the Special Protocol Assessment (SPA) process for a Phase 3 clinical trial evaluating fosmetpantotenate (RE-024) for PKAN. The Company </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">has reviewed the study design with the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> European Medicines Agency ("EMA") </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">and we expect it to support registration in Europe.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> In July 2017, we</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> announced that the first patient had been dosed in the FORT (FOsmetpantotenate Replacement Therapy) Study.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan, also known as RE-021, is an investigational therapeutic agent which acts as both a potent angiotensin receptor blocker (“ARB”), as well as a selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A. The Company has secured a license to sparsentan from Ligand Pharmaceuticals, Inc. and Bristol-Myers Squibb Company (who referred to it as DARA). The Company is developing sparsentan as a treatment for focal segmental glomerulosclerosis ("FSGS"), which is a leading cause of end-stage renal disease and nephrotic syndrome (“NS”). Sparsentan was granted orphan drug designation in the United States and the European Union in January 2015 and November 2015, respectively. In the third quarter of 2016, the Company announced positive top-line data from the Phase 2 DUET study of sparsentan for the treatment of FSGS. In early 2017, we had</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"> </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">an End of Phase 2 meeting with the U.S. Food and Drug Administration (the "FDA") regarding the regulatory pathway for sparsentan as a treatment for FSGS.  Following the meeting and our receipt of confirmatory meeting minutes, we announced our plans to initiate a single Phase 3 clinical trial to serve as the basis of a New Drug Application ("NDA") filing for sparsentan for the treatment of FSGS. During the third quarter of 2017, we </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">submitted the Phase 3 protocol for review to the FDA, and on November 6, 2017, we received feedback from the FDA requesting additional quantitative analyses to support the trial design’s eligibility for the Subpart H accelerated approval pathway. Study start-up activities continue and we anticipate initiating the pivotal trial in 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">N-glycanase deficiency, or NGLY1 deficiency, is an extremely rare genetic disorder believed to be caused by a deficiency in an enzyme called N-glycanase-1, which is encoded by the gene NGLY1. The condition has been characterized by symptoms such as developmental delays, seizures, complex hyperkinetic movement disorders, diminished reflexes and an inability to produce tears. There are no approved therapeutic options for NGLY1 deficiency, and current therapeutic strategies are limited to symptom management.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In September 2017, we announced that we entered a three-way Cooperative Research and Development Agreement ("CRADA") </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) and patient advocacy foundation NGLY1.org</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> to collaborate on research efforts aimed at the identification of potential small molecule therapeutics for NGLY1 deficiency.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Liquid ursodeoxycholic acid ("L-UDCA") is a liquid formulation of ursodeoxycholic acid being developed for the treatment of a rare liver disease called primary biliary cholangitis ("PBC"). We obtained rights to L-UDCA during 2016 with the intention of making L-UDCA commercially available to the subset of PBC patients who have difficulty swallowing. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">Products on the Market:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">®</sup></font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (chenodiol) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has been the standard of care for cerebrotendinous xanthomatosis ("CTX") patients for more than three decades and the Company is currently pursuing adding this indication to the label.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cholbam</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">®</sup></font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (cholic acid) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">®</sup></font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (tiopronin) is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</font></div></td></tr></table></div>

Files In Submission

Name	View Source	Status
0001438533-17-000034-index-headers.html	Edgar Link	pending
0001438533-17-000034-index.html	Edgar Link	pending
0001438533-17-000034.txt	Edgar Link	pending
0001438533-17-000034-xbrl.zip	Edgar Link	pending
ex09302017311.htm	Edgar Link	pending
ex09302017312.htm	Edgar Link	pending
ex09302017321.htm	Edgar Link	pending
ex09302017322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipelineq22017a03.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rtrx-20170930.xml	Edgar Link	completed
rtrx-20170930.xsd	Edgar Link	pending
rtrx-20170930x10q.htm	Edgar Link	pending
rtrx-20170930_cal.xml	Edgar Link	unprocessable
rtrx-20170930_def.xml	Edgar Link	unprocessable
rtrx-20170930_lab.xml	Edgar Link	unprocessable
rtrx-20170930_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics Inc Stock $tvtx

2017 Q4 Form 10-Q Financial Statement

#000143853317000034 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics Inc Stock $tvtx

2017 Q4 Form 10-Q Financial Statement

#000143853317000034 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics Inc Stock $tvtx